Cargando…
Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL?
BACKGROUND: Neurocognitive impairments are common among brain tumor patients, and may impact patients’ awareness of performance in instrumental activities in daily life (IADL). We examined differences between patient- and proxy-reported assessments of the patient’s IADL, and whether the level of (di...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290871/ https://www.ncbi.nlm.nih.gov/pubmed/35855454 http://dx.doi.org/10.1093/nop/npac016 |
_version_ | 1784749010792218624 |
---|---|
author | Oort, Quirien Dirven, Linda Sikkes, Sietske A M Aaronson, Neil Boele, Florien Brannan, Christine Egeter, Jonas Grant, Robin Klein, Martin Lips, Irene M Narita, Yoshitaka Sato, Hitomi Sztankay, Monika Stockhammer, Günther Talacchi, Andrea Uitdehaag, Bernard M J Reijneveld, Jaap C Taphoorn, Martin J B |
author_facet | Oort, Quirien Dirven, Linda Sikkes, Sietske A M Aaronson, Neil Boele, Florien Brannan, Christine Egeter, Jonas Grant, Robin Klein, Martin Lips, Irene M Narita, Yoshitaka Sato, Hitomi Sztankay, Monika Stockhammer, Günther Talacchi, Andrea Uitdehaag, Bernard M J Reijneveld, Jaap C Taphoorn, Martin J B |
author_sort | Oort, Quirien |
collection | PubMed |
description | BACKGROUND: Neurocognitive impairments are common among brain tumor patients, and may impact patients’ awareness of performance in instrumental activities in daily life (IADL). We examined differences between patient- and proxy-reported assessments of the patient’s IADL, and whether the level of (dis)agreement is associated with neurocognitive impairments. METHODS: Brain tumor patients and their proxies completed the phase 3 version of the EORTC IADL-BN32 questionnaire measuring IADL, and patients completed six neurocognitive measures. Patient-proxy difference scores in IADL were compared between patients who were defined as neurocognitively impaired (≥2 neurocognitive measures ≥2.0 standard deviations below healthy controls) and non-neurocognitively impaired. With multinomial logistic regression analyses we examined if neurocognitive variables were independently associated with patient-proxy disagreement in IADL ratings. RESULTS: Patients (n = 81) did not systematically (P < .01) rate IADL outcomes different than their proxies. Proxies did report more problems on 19/32 individual items and all five scales. This effect was more apparent in dyads with a neurocognitively impaired patient (n = 37), compared to dyads with non-neurocognitively impaired patients (n = 44). Multinomial logistic regression analyses showed that several neurocognitive variables (e.g., cognitive flexibility and verbal fluency) were independently associated with disagreement between patients and proxies on different scales. CONCLUSION: Neurocognitive deficits seem to play a role in the discrepancies between brain tumor patients and their proxies assessment of patient’s level of IADL. Although replication of our results is needed, our findings suggests that caution is warranted in interpreting self-reported IADL by patients with neurocognitive impairment, and that such self-reports should be supplemented with proxy ratings. |
format | Online Article Text |
id | pubmed-9290871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92908712022-07-18 Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL? Oort, Quirien Dirven, Linda Sikkes, Sietske A M Aaronson, Neil Boele, Florien Brannan, Christine Egeter, Jonas Grant, Robin Klein, Martin Lips, Irene M Narita, Yoshitaka Sato, Hitomi Sztankay, Monika Stockhammer, Günther Talacchi, Andrea Uitdehaag, Bernard M J Reijneveld, Jaap C Taphoorn, Martin J B Neurooncol Pract Original Articles BACKGROUND: Neurocognitive impairments are common among brain tumor patients, and may impact patients’ awareness of performance in instrumental activities in daily life (IADL). We examined differences between patient- and proxy-reported assessments of the patient’s IADL, and whether the level of (dis)agreement is associated with neurocognitive impairments. METHODS: Brain tumor patients and their proxies completed the phase 3 version of the EORTC IADL-BN32 questionnaire measuring IADL, and patients completed six neurocognitive measures. Patient-proxy difference scores in IADL were compared between patients who were defined as neurocognitively impaired (≥2 neurocognitive measures ≥2.0 standard deviations below healthy controls) and non-neurocognitively impaired. With multinomial logistic regression analyses we examined if neurocognitive variables were independently associated with patient-proxy disagreement in IADL ratings. RESULTS: Patients (n = 81) did not systematically (P < .01) rate IADL outcomes different than their proxies. Proxies did report more problems on 19/32 individual items and all five scales. This effect was more apparent in dyads with a neurocognitively impaired patient (n = 37), compared to dyads with non-neurocognitively impaired patients (n = 44). Multinomial logistic regression analyses showed that several neurocognitive variables (e.g., cognitive flexibility and verbal fluency) were independently associated with disagreement between patients and proxies on different scales. CONCLUSION: Neurocognitive deficits seem to play a role in the discrepancies between brain tumor patients and their proxies assessment of patient’s level of IADL. Although replication of our results is needed, our findings suggests that caution is warranted in interpreting self-reported IADL by patients with neurocognitive impairment, and that such self-reports should be supplemented with proxy ratings. Oxford University Press 2022-02-26 /pmc/articles/PMC9290871/ /pubmed/35855454 http://dx.doi.org/10.1093/nop/npac016 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Oort, Quirien Dirven, Linda Sikkes, Sietske A M Aaronson, Neil Boele, Florien Brannan, Christine Egeter, Jonas Grant, Robin Klein, Martin Lips, Irene M Narita, Yoshitaka Sato, Hitomi Sztankay, Monika Stockhammer, Günther Talacchi, Andrea Uitdehaag, Bernard M J Reijneveld, Jaap C Taphoorn, Martin J B Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL? |
title | Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL? |
title_full | Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL? |
title_fullStr | Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL? |
title_full_unstemmed | Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL? |
title_short | Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s IADL? |
title_sort | do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient’s iadl? |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290871/ https://www.ncbi.nlm.nih.gov/pubmed/35855454 http://dx.doi.org/10.1093/nop/npac016 |
work_keys_str_mv | AT oortquirien doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT dirvenlinda doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT sikkessietskeam doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT aaronsonneil doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT boeleflorien doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT brannanchristine doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT egeterjonas doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT grantrobin doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT kleinmartin doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT lipsirenem doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT naritayoshitaka doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT satohitomi doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT sztankaymonika doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT stockhammergunther doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT talacchiandrea doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT uitdehaagbernardmj doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT reijneveldjaapc doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl AT taphoornmartinjb doneurocognitiveimpairmentsexplainthedifferencesbetweenbraintumorpatientsandtheirproxieswhenassessingthepatientsiadl |